Welcome to our dedicated page for Edesa Biotech news (Ticker: EDSA), a resource for investors and traders seeking the latest updates and insights on Edesa Biotech stock.
Edesa Biotech reports developments as a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases. Its recurring news centers on paridiprubart, or EB05, an anti-TLR4 antibody evaluated for Acute Respiratory Distress Syndrome, and EB06, an anti-CXCL10 monoclonal antibody program for moderate-to-severe nonsegmental vitiligo.
Company updates also cover clinical data presentations, manufacturing and regulatory preparation, government-supported research activities, conference participation, operating results, capital-structure matters and shareholder governance. Financial reports generally frame spending around clinical development priorities and the company’s monoclonal antibody pipeline.
Edesa Biotech (Nasdaq:EDSA) has received Fast Track designation from the FDA for its monoclonal antibody candidate EB05, aimed at treating Acute Respiratory Distress Syndrome (ARDS)/b) in hospitalized Covid-19 patients. This designation facilitates accelerated communication with the FDA and potential faster regulatory approval. Positive Phase 2 trial results showed an in mortality risk for patients receiving EB05 compared to a placebo. The Fast Track program aims to address serious diseases and unmet medical needs.
Edesa Biotech, Inc. (NASDAQ:EDSA) reported its financial results for the fiscal year ending September 30, 2022. The company achieved an 84% reduction in the risk of death for critically ill COVID-19 patients receiving its monoclonal antibody, EB05. Total operating expenses fell over 20% to $18.37 million, with a net loss of $17.55 million for the year. Edesa reported cash and cash equivalents of $7.09 million as of September 30. The company has ongoing Phase 3 clinical protocol reviews and anticipates significant progress in 2023.
Edesa Biotech (NASDAQ:EDSA), a clinical-stage biopharmaceutical firm, announced Dr. Par Nijhawan's participation in the panel discussion at the Cantor Fitzgerald Medical Dermatology, Ophthalmology & Medtech Conference on December 8, 2022, at 10:00 am ET. Meetings can be arranged through Cantor representatives or directly at investors@edesabiotech.com. Edesa is focused on treatments for immune-related diseases, with lead candidates EB01 (Phase 2b) for allergic contact dermatitis and EB05 (Phase 3) for Acute Respiratory Distress Syndrome.
Edesa Biotech (NASDAQ:EDSA) announced the closing of a $3.0 million private placement priced at-the-market. The offering included 2,691,337 common shares, alongside 12-month and 3-year warrants for an additional 1,345,665 shares each. The common shares were sold at $1.125 each. Proceeds will support clinical programs, including a Phase 2b study for allergic contact dermatitis. Notably, officers and directors invested approximately $0.5 million in this offering. This transaction is registered under Section 4(a)(2) of the Securities Act.
Edesa Biotech reported favorable final results from the Phase 2 study of its monoclonal antibody candidate EB05 for treating Covid-19 induced ARDS. The study demonstrated an 84% reduction in mortality risk at 28 days for critically ill patients receiving EB05 compared to placebo (7.7% vs. 40%, p=0.04). A Clinical Study Report has been submitted to the FDA, and the company is advancing to Phase 3 trials.
EB05 may address significant unmet needs in ARDS treatment caused by various pathogens. The study was partially funded by a C$14 million government grant.
Edesa Biotech (NASDAQ:EDSA) announced that CEO Par Nijhawan will present at the H.C. Wainwright Global Investment Conference in New York from September 12-14, 2022. The presentation is scheduled for September 12 at 10:00 am Eastern Time, and slides will be available on the Edesa website. Edesa is focused on developing treatments for inflammatory diseases, with key products, EB05 for ARDS and EB01 for chronic allergic contact dermatitis, in late-stage studies.
Edesa Biotech (NASDAQ:EDSA) has completed patient recruitment for its Phase 2b clinical study of EB01, a non-steroidal anti-inflammatory drug candidate for moderate-to-severe chronic Allergic Contact Dermatitis. The primary endpoint is expected to be reached within 30 days, with topline data anticipated by year-end. The company is exploring out-licensing opportunities outside North America and prioritizing future clinical studies for EB01. Interim results show promising efficacy, with significant differences reported in key endpoints compared to placebo, and no serious adverse events were recorded.
Edesa Biotech (NASDAQ:EDSA) reported financial results for Q3 and nine months ended June 30, 2022. The company expanded its Phase 3 drug study for Covid-19 patients and confirmed robust recruitment for its Phase 2b dermatology study. Q3 operational expenses decreased to $5.80 million, while net loss was $5.79 million. For the nine months, total operating expenses dropped to $15.53 million, with a net loss of $14.74 million. Edesa holds $12.81 million in cash, with plans to participate in the H.C. Wainwright Global Investment Conference in September 2022.
Edesa Biotech (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, will partake in the BTIG Biotechnology Conference in New York on August 8-9, 2022. This hybrid event allows for both virtual and in-person attendance. Interested parties can connect with Edesa through BTIG representatives or via email at investors@edesabiotech.com. Edesa is advancing two critical product candidates, EB05, targeting Acute Respiratory Distress Syndrome, and EB01, for chronic allergic contact dermatitis.
Edesa Biotech, focusing on inflammatory and immune-related diseases, will present at the 2nd Annual ARDS Drug Development Summit on July 14, 2022, in Boston. CEO Par Nijhawan is set to discuss the EB05 drug candidate, a potential treatment for Acute Respiratory Distress Syndrome (ARDS), highlighting its Phase 2/3 clinical trial design influenced by Covid-19. Edesa's EB05 has shown a promising 68.5% reduction in mortality among critically ill Covid-19 patients. Additionally, the press release provides insights into the company's clinical programs for EB01 and their ongoing studies.